{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:41:45Z","timestamp":1790959305377,"version":"4.1.0"},"reference-count":97,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100008530","name":"Spanish Ministry of Economy and Competitiveness, and European Regional Development Fund","doi-asserted-by":"publisher","award":["PN 2018-2021"],"award-info":[{"award-number":["PN 2018-2021"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP16\/00082"],"award-info":[{"award-number":["CP16\/00082"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2019,6,19]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Alzheimer\u2019s disease (AD), the most common cause of dementia in adulthood, has great medical, social, and economic impact worldwide. Available treatments result in symptomatic relief, and most of them are indicated from the early stages of the disease. Therefore, there is an increasing body of research developing accurate and early diagnoses, as well as diseasemodifying therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Advancing the knowledge of AD physiopathological mechanisms, improving early diagnosis and developing effective treatments from omics-based biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Studies using omics technologies to detect early AD, were reviewed with a particular focus on the metabolites\/lipids, micro-RNAs and proteins, which are identified as potential biomarkers in non-invasive samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>This review summarizes recent research on metabolomics\/lipidomics, epigenomics and proteomics, applied to early AD detection. Main research lines are the study of metabolites from pathways, such as lipid, amino acid and neurotransmitter metabolisms, cholesterol biosynthesis, and Krebs and urea cycles. In addition, some microRNAs and proteins (microglobulins, interleukins), related to a common network with amyloid precursor protein and tau, have been also identified as potential biomarkers. Nevertheless, the reproducibility of results among studies is not good enough and a standard methodological approach is needed in order to obtain accurate information.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The assessment of metabolomic\/lipidomic, epigenomic and proteomic changes associated with AD to identify early biomarkers in non-invasive samples from well-defined participants groups will potentially allow the advancement in the early diagnosis and improvement of therapeutic interventions.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1570159x16666180926123722","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T12:00:25Z","timestamp":1537963225000},"page":"630-647","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Omics-based Biomarkers for the Early Alzheimer Disease Diagnosis and Reliable Therapeutic Targets Development"],"prefix":"10.2174","volume":"17","author":[{"given":"Carmen","family":"Pe\u00f1a-Bautista","sequence":"first","affiliation":[{"name":"Neonatal Research Unit, Health Research Institute La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Baquero","sequence":"additional","affiliation":[{"name":"Neurology Unit, University and Polytechnic Hospital La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ximo","family":"Vento","sequence":"additional","affiliation":[{"name":"Neonatal Research Unit, Health Research Institute La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Ch\u00e1fer-Peric\u00e1s","sequence":"additional","affiliation":[{"name":"Neonatal Research Unit, Health Research Institute La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"227","volume":"33","author":"Duckett L.","year":"2001","unstructured":"Duckett L. Alzheimer\u2019s dementia: morbidity and mortality.","journal-title":"J Insur Med"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","volume":"11","author":"Qiu C.","year":"2009","unstructured":"Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer\u2019s disease: occurrence, determinants, and strategies toward intervention.","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=3","unstructured":"www.alzheimer-europe.org. 2008."},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"Brookmeyer R.","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer\u2019s disease.","journal-title":"Alzheimers Dement"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.2165\/11595870-000000000-00000","volume":"71","author":"Herrmann N.","year":"2011","unstructured":"Herrmann N, Chau SA, Kircanski I, Lanct\u00f4t KL. Current and emerging drug treatment options for Alzheimer\u2019s disease: a systematic review.","journal-title":"Drugs"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jalz.2011.10.008","volume":"8","author":"Visser P.J.","year":"2012","unstructured":"Visser PJ, Vos S, van Rossum I, Scheltens P. Comparison of International Working Group criteria and National Institute on Aging-Alzheimer\u2019s Association criteria for Alzheimer\u2019s disease.","journal-title":"Alzheimers Dement"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jalz.2014.05.1754","volume":"11","author":"Bertens D.","year":"2015","unstructured":"Bertens D, Knol DL, Scheltens P, Visser PJ. Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer\u2019s disease.","journal-title":"Alzheimers Dement"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"Albert M.S.","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","journal-title":"Alzheimers Dement"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"McKhann G.M.","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","journal-title":"Alzheimers Dement"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"Hughes C.P.","year":"1982","unstructured":"Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia.","journal-title":"Br J Psychiatry"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","volume":"139","author":"Reisberg B.","year":"1982","unstructured":"Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia.","journal-title":"Am J Psychiatry"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fneur.2015.00152","volume":"6","author":"Moretti D.V.","year":"2015","unstructured":"Moretti DV. Mild cognitive impairment: structural, metabolical, and neurophysiological evidence of a novel EEG biomarker.","journal-title":"Front Neurol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JAD-143006","volume":"47","author":"Lista S.","year":"2015","unstructured":"Lista S, O\u2019Bryant SE, Blennow K, Dubois B, Hugon J, Zetterberg H, Hampel H. Biomarkers in Sporadic and Familial Alzheimer\u2019s Disease.","journal-title":"J Alzheimers Dis"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/jnen\/59.12.1118","volume":"59","author":"Terry R.D.","year":"2000","unstructured":"Terry RD. Cell death or synaptic loss in Alzheimer disease.","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/138920311795860214","volume":"12","author":"Mohamed A.","year":"2011","unstructured":"Mohamed A, Cortez L, de Chaves EP. Aggregation state and neurotoxic properties of alzheimer \u03b2-amyloid peptide.","journal-title":"Curr Protein Pept Sci"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"Lane C.A.","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer\u2019s disease.","journal-title":"Eur J Neurol"},{"key":"ref=17","unstructured":"Le Page, A.; Dupuis, G.; Frost, E.H.; Larbi, A.; Pawelec, G.; Witkowski, J.M.; Fulop, T. Role of the peripheral innate immune system in the development of Alzheimer's disease. Exp. Gerontol.,, 2017. S0531-5565, 30541-30547."},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1152\/ajpcell.00109.2017","volume":"313","author":"Pimplikar S.W.","year":"2017","unstructured":"Pimplikar SW. Multi-omics and Alzheimer\u2019s disease: a slower but surer path to an efficacious therapy?","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"C3","DOI":"10.1152\/ajpcell.00007.2017","volume":"313","author":"Zetterberg H.","year":"2017","unstructured":"Zetterberg H. Applying fluid biomarkers to Alzheimer\u2019s disease.","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrm3314","volume":"13","author":"Patti G.J.","year":"2012","unstructured":"Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neurobiolaging.2015.11.014","volume":"38","author":"Pan X.","year":"2016","unstructured":"Pan X, Nasaruddin MB, Elliott CT, McGuinness B, Passmore AP, Kehoe PG, H\u00f6lscher C, McClean PL, Graham SF, Green BD. Alzheimer\u2019s disease-like pathology has transient effects on the brain and blood metabolome.","journal-title":"Neurobiol Aging"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1021\/pr5000895","volume":"13","author":"Wang G.","year":"2014","unstructured":"Wang G, Zhou Y, Huang FJ, Tang HD, Xu XH, Liu JJ, Wang Y, Deng YL, Ren RJ, Xu W, Ma JF, Zhang YN, Zhao AH, Chen SD, Jia W. Plasma metabolite profiles of Alzheimer\u2019s disease and mild cognitive impairment.","journal-title":"J Proteome Res"},{"key":"ref=23","volume":"6","author":"Han X.","year":"2011","unstructured":"Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM, Kaddurah-Daouk R. Metabolomics in early Alzheimer\u2019s disease: identification of altered plasma sphingolipidome using shotgun lipidomics.","journal-title":"PLoS One"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamaneurol.2014.3049","volume":"72","author":"Yu L.","year":"2015","unstructured":"Yu L, Chibnik LB, Srivastava GP, Pochet N, Yang J, Xu J, Kozubek J, Obholzer N, Leurgans SE, Schneider JA, Meissner A, De Jager PL, Bennett DA. Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease.","journal-title":"JAMA Neurol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-150451","volume":"49","author":"Pan Y.","year":"2016","unstructured":"Pan Y, Liu R, Terpstra E, Wang Y, Qiao F, Wang J, Tong Y, Pan B. Dysregulation and diagnostic potential of microRNA in Alzheimer\u2019s disease.","journal-title":"J Alzheimers Dis"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1089\/omi.2016.0099","volume":"20","author":"Y\u0131lmaz \u015e.G.","year":"2016","unstructured":"Y\u0131lmaz \u015eG, Erdal ME, \u00d6zge AA, Sungur MA. Can Peripheral MicroRNA Expression Data Serve as Epigenomic (Upstream) Biomarkers of Alzheimer\u2019s Disease?","journal-title":"OMICS"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fgene.2013.00150","volume":"4","author":"Cheng L.","year":"2013","unstructured":"Cheng L, Quek CY, Sun X, Bellingham SA, Hill AF. The detection of microRNA associated with Alzheimer\u2019s disease in biological fluids using next-generation sequencing technologies.","journal-title":"Front Genet"},{"key":"ref=28","first-page":"1005","volume":"12","author":"Wyss-Coray T.","year":"2006","unstructured":"Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?","journal-title":"Nat Med"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"Ray S.","year":"2007","unstructured":"Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T. Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins.","journal-title":"Nat Med"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/WAD.0b013e31827b60d2","volume":"27","author":"Guo L.H.","year":"2013","unstructured":"Guo LH, Alexopoulos P, Wagenpfeil S, Kurz A, Perneczky R. Plasma proteomics for the identification of Alzheimer disease.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1017\/S1041610297004717","volume":"9","author":"Petersen R.C.","year":"1997","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment.","journal-title":"Int Psychogeriatr"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"McKhann G.","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease.","journal-title":"Neurology"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2174\/1567205013666160129095138","volume":"13","author":"Gonz\u00e1lez-Dom\u00ednguez R.","year":"2016","unstructured":"Gonz\u00e1lez-Dom\u00ednguez R, Rup\u00e9rez FJ, Garc\u00eda-Barrera T, Barbas C, G\u00f3mez-Ariza JL. Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer\u2019s Disease and Mild Cognitive Impairment.","journal-title":"Curr Alzheimer Res"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1002\/elps.201400196","volume":"35","author":"Gonz\u00e1lez-Dom\u00ednguez R.","year":"2014","unstructured":"Gonz\u00e1lez-Dom\u00ednguez R, Garc\u00eda A, Garc\u00eda-Barrera T, Barbas C, G\u00f3mez-Ariza JL. Metabolomic profiling of serum in the progression of Alzheimer\u2019s disease by capillary electrophoresis-mass spectrometry.","journal-title":"Electrophoresis"},{"key":"ref=35","volume":"10","author":"Graham S.F.","year":"2015","unstructured":"Graham SF, Chevallier OP, Elliott CT, H\u00f6lscher C, Johnston J, McGuinness B, Kehoe PG, Passmore AP, Green BD. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer\u2019s disease.","journal-title":"PLoS One"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neurobiolaging.2016.11.007","volume":"51","author":"Mapstone M.","year":"2017","unstructured":"Mapstone M, Lin F, Nalls MA, Cheema AK, Singleton AB, Fiandaca MS, Federoff HJ. What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer\u2019s disease.","journal-title":"Neurobiol Aging"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.dadm.2017.07.006","volume":"8","author":"de Leeuw F.A.","year":"2017","unstructured":"de Leeuw FA, Peeters CFW, Kester MI, Harms AC, Struys EA, Hankemeier T, van Vlijmen HWT, van der Lee SJ, van Duijn CM, Scheltens P, Demirkan A, van de Wiel MA, van der Flier WM, Teunissen CE. Blood-based metabolic signatures in Alzheimer\u2019s disease.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3233\/JAD-142925","volume":"45","author":"Olazar\u00e1n J.","year":"2015","unstructured":"Olazar\u00e1n J, Gil-de-G\u00f3mez L, Rodr\u00edguez-Mart\u00edn A, Valent\u00ed-Soler M, Frades-Payo B, Mar\u00edn-Mu\u00f1oz J, Ant\u00fanez C, Frank-Garc\u00eda A, Acedo-Jim\u00e9nez C, Morl\u00e1n-Gracia L, Petidier-Torregrossa R, Guisasola MC, Bermejo-Pareja F, S\u00e1nchez-Ferro \u00c1, P\u00e9rez-Mart\u00ednez DA, Manzano-Palomo S, Farquhar R, R\u00e1bano A, Calero M. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer\u2019s disease.","journal-title":"J Alzheimers Dis"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Toledo, J.B.; Arnold, M.; Kastenm\u00fcller, G.; Chang, R.; Baillie, R.A.; Han, X.; Thambisetty, M.; Tenenbaum, J.D.; Suhre, K.; Thompson, J.W.; John-Williams, L.S.; Mahmoudian, D.S.; Rotroff, D.M.; Jack, J.R.; Motsinger-Reif, A.; Risacher, S.L.; Blach, C.; Lucas, J.E.; Massaro, T.; Louie, G.; Zhu, H.; Dallmann, G.; Klavins, K.; Koal, T.; Kim, S.; Nho, K.; Shen, L.; Casanova, R.; Varma, S.; Legido-Quigley, C.; Moseley, M.A.; Zhu, K.; Henrion, M.Y.R.; van der Lee, S.J.; Harms, A.C.; Demirkan, A.; Hankemeier, T. van Duijn, C.M.; Trojanowski, J.Q.; Shaw, L.M.; Saykin, A.J.; Weiner, M.W.; Doraiswamy, P.M.; Kaddurah-Daouk, R. Metabolic network failures in Alzheimer\u2019s disease: A biochemical road map. Alzheimers Dement., 2017, 13(9), 965-984. [http:\/\/dx.doi.org\/10.1016\/j.jalz.2017.01.020]. [PMID: 28341160]","DOI":"10.1016\/j.jalz.2017.01.020"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jalz.2017.04.009","volume":"13","author":"Chouraki V.","year":"2017","unstructured":"Chouraki V, Preis SR, Yang Q, Beiser A, Li S, Larson MG, Weinstein G, Wang TJ, Gerszten RE, Vasan RS, Seshadri S. Association of amine biomarkers with incident dementia and Alzheimer\u2019s disease in the Framingham Study.","journal-title":"Alzheimers Dement"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3389\/fnins.2017.00747","volume":"11","author":"Ore\u0161i\u010d M.","year":"2018","unstructured":"Ore\u0161i\u010d M, Anderson G, Mattila I, Manoucheri M, Soininen H, Hy\u00f6tyl\u00e4inen T, Basignani C. Targeted Serum Metabolite Profiling Identifies Metabolic Signatures in Patients with Alzheimer\u2019s Disease, Normal Pressure Hydrocephalus and Brain Tumor.","journal-title":"Front Neurosci"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JAD-160172","volume":"57","author":"Oberacher H.","year":"2017","unstructured":"Oberacher H, Arnhard K, Linhart C, Diwo A, Marksteiner J, Humpel C. Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer\u2019s Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?","journal-title":"J Alzheimers Dis"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1871524915666141216161246","volume":"14","author":"Liu Y.","year":"2014","unstructured":"Liu Y, Li N, Zhou L, Li Q, Li W. Plasma metabolic profiling of mild cognitive impairment and Alzheimer\u2019s disease using liquid chromatography\/mass spectrometry.","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.dadm.2016.02.008","volume":"3","author":"Li D.","year":"2016","unstructured":"Li D, Misialek JR, Boerwinkle E, Gottesman RF, Sharrett AR, Mosley TH, Coresh J, Wruck LM, Knopman DS, Alonso A. Plasma phospholipids and prevalence of mild cognitive impairment and\/or dementia in the ARIC Neurocognitive Study (ARIC-NCS).","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neurobiolaging.2013.08.001","volume":"35","author":"Whiley L.","year":"2014","unstructured":"Whiley L, Sen A, Heaton J, Proitsi P, Garc\u00eda-G\u00f3mez D, Leung R, Smith N, Thambisetty M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Lovestone S, Legido-Quigley C. Evidence of altered phosphatidylcholine metabolism in Alzheimer\u2019s disease.","journal-title":"Neurobiol Aging"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/0271678X15611678","volume":"36","author":"Simpson B.N.","year":"2016","unstructured":"Simpson BN, Kim M, Chuang YF, Beason-Held L, Kitner-Triolo M, Kraut M, Lirette ST, Windham BG, Griswold ME, Legido-Quigley C, Thambisetty M. Blood metabolite markers of cognitive performance and brain function in aging.","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=47","first-page":"1","volume":"6","author":"Li D.","year":"2016","unstructured":"Li D, Misialek JR, Boerwinkle E, Gottesman RF, Sharrett AR, Mosley TH, Coresh J, Wruck LM, Knopman DS, Alonso A. Prospective associations of plasma phospholipids and mild cognitive impairment\/dementia among African Americans in the ARIC Neurocognitive Study.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3233\/JAD-122224","volume":"36","author":"Iuliano L.","year":"2013","unstructured":"Iuliano L, Pacelli A, Ciacciarelli M, Zerbinati C, Fagioli S, Piras F, Orfei MD, Boss\u00f9 P, Pazzelli F, Serviddio G, Caltagirone C, Spalletta G. Plasma fatty acid lipidomics in amnestic mild cognitive impairment and Alzheimer\u2019s disease.","journal-title":"J Alzheimers Dis"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jalz.2016.08.003","volume":"13","author":"Proitsi P.","year":"2017","unstructured":"Proitsi P, Kim M, Whiley L, Simmons A, Sattlecker M, Velayudhan L, Lupton MK, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Powell JF, Dobson RJ, Legido-Quigley C. Association of blood lipids with Alzheimer\u2019s disease: A comprehensive lipidomics analysis.","journal-title":"Alzheimers Dement"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Proitsi, P.; Kim, M.; Whiley, L.; Pritchard, M.; Leung, R.; Soininen, H.; Kloszewska, I.; Mecocci, P.; Tsolaki, M.; Vellas, B.; Sham, P.; Lovestone, S.; Powell, J.F.; Dobson, R.J.; Legido-Quigley, C. Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer\u2019s disease. Transl. Psychiatry, 2015. 5e494 [http:\/\/dx.doi.org\/10.1038\/tp.2014.127] [PMID: 25585166]","DOI":"10.1038\/tp.2014.127"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2016.03.005","volume":"43","author":"Ciavardelli D.","year":"2016","unstructured":"Ciavardelli D, Piras F, Consalvo A, Rossi C, Zucchelli M, Di Ilio C, Frazzini V, Caltagirone C, Spalletta G, Sensi SL. Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer\u2019s disease subjects.","journal-title":"Neurobiol Aging"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.dadm.2016.02.005","volume":"3","author":"Savica R.","year":"2016","unstructured":"Savica R, Murray ME, Persson XM, Kantarci K, Parisi JE, Dickson DW, Petersen RC, Ferman TJ, Boeve BF, Mielke MM. Plasma sphingolipid changes with autopsy-confirmed Lewy Body or Alzheimer\u2019s pathology.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.dadm.2015.05.003","volume":"1","author":"Klavins K.","year":"2015","unstructured":"Klavins K, Koal T, Dallmann G, Marksteiner J, Kemmler G, Humpel C. The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer\u2019s disease and mild cognitive impairment.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbacli.2015.11.004","volume":"5","author":"Wood P.L.","year":"2015","unstructured":"Wood PL, Locke VA, Herling P, Passaro A, Vigna GB, Volpato S, Valacchi G, Cervellati C, Zuliani G. Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer\u2019s disease (LOAD).","journal-title":"BBA Clin"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/JAD-161226","volume":"58","author":"Yilmaz A.","year":"2017","unstructured":"Yilmaz A, Geddes T, Han B, Bahado-Singh RO, Wilson GD, Imam K, Maddens M, Graham SF. Diagnostic Biomarkers of Alzheimer\u2019s Disease as Identified in Saliva using 1H NMR-Based Metabolomics.","journal-title":"J Alzheimers Dis"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.aca.2015.06.028","volume":"886","author":"Ch\u00e1fer-Peric\u00e1s C.","year":"2015","unstructured":"Ch\u00e1fer-Peric\u00e1s C, Rahkonen L, S\u00e1nchez-Illana A, Kuligowski J, Torres-Cuevas I, Cernada M, Cubells E, Nu\u00f1ez-Ramiro A, Andersson S, Vento M, Escobar J. Ultra high performance liquid chromatography coupled to tandem mass spectrometry determination of lipid peroxidation biomarkers in newborn serum samples.","journal-title":"Anal Chim Acta"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.talanta.2016.03.010","volume":"153","author":"Ch\u00e1fer-Peric\u00e1s C.","year":"2016","unstructured":"Ch\u00e1fer-Peric\u00e1s C, Torres-Cuevas I, Sanchez-Illana A, Escobar J, Kuligowski J, Solberg R, Garberg HT, Huun MU, Saugstad OD, Vento M. Development of a reliable analytical method to determine lipid peroxidation biomarkers in newborn plasma samples.","journal-title":"Talanta"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jpba.2016.02.007","volume":"123","author":"Escobar J.","year":"2016","unstructured":"Escobar J, S\u00e1nchez-Illana \u00c1, Kuligowski J, Torres-Cuevas I, Solberg R, Garberg HT, Huun MU, Saugstad OD, Vento M, Ch\u00e1fer-Peric\u00e1s C. Development of a reliable method based on ultra-performance liquid chromatography coupled to tandem mass spectrometry to measure thiol-associated oxidative stress in whole blood samples.","journal-title":"J Pharm Biomed Anal"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.talanta.2018.03.002","volume":"184","author":"Garc\u00eda-Blanco A.","year":"2018","unstructured":"Garc\u00eda-Blanco A, Pe\u00f1a-Bautista C, Oger C, Vigor C, Galano JM, Durand T, Mart\u00edn-Ib\u00e1\u00f1ez N, Baquero M, Vento M, Ch\u00e1fer-Peric\u00e1s C. Reliable determination of new lipid peroxidation compounds as potential early Alzheimer Disease biomarkers.","journal-title":"Talanta"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.freeradbiomed.2018.06.038","volume":"124","author":"Pe\u00f1a-Bautista C.","year":"2018","unstructured":"Pe\u00f1a-Bautista C, Vigor C, Galano JM, Oger C, Durand T, Ferrer I, Cuevas A, L\u00f3pez-Cuevas R, Baquero M, L\u00f3pez-Nogueroles M, Vento M, Herv\u00e1s D, Garc\u00eda-Blanco A, Ch\u00e1fer-Peric\u00e1s C. Plasma lipid peroxidation biomarkers for early and non-invasive Alzheimer Disease detection.","journal-title":"Free Radic Biol Med"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cca.2012.05.021","volume":"413","author":"Garc\u00eda-Gim\u00e9nez J.L.","year":"2012","unstructured":"Garc\u00eda-Gim\u00e9nez JL, Sanchis-Gomar F, Lippi G, Mena S, Ivars D, Gomez-Cabrera MC, Vi\u00f1a J, Pallard\u00f3 FV. Epigenetic biomarkers: A new perspective in laboratory diagnostics.","journal-title":"Clin Chim Acta"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/1756-0500-7-581","volume":"7","author":"Taguchi Y.H.","year":"2014","unstructured":"Taguchi YH, Murakami Y. Universal disease biomarker: can a fixed set of blood microRNAs diagnose multiple diseases?","journal-title":"BMC Res Notes"},{"key":"ref=63","volume":"2015","author":"Dong H.","year":"2015","unstructured":"Dong H, Li J, Huang L, Chen X, Li D, Wang T, Hu C, Xu J, Zhang C, Zen K, Xiao S, Yan Q, Wang C, Zhang CY. Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer\u2019s Disease.","journal-title":"Dis Markers"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4137\/BMI.S25132","volume":"10","author":"Satoh J.","year":"2015","unstructured":"Satoh J, Kino Y, Niida S. MicroRNA-Seq Data Analysis Pipeline to Identify Blood Biomarkers for Alzheimer\u2019s Disease from Public Data.","journal-title":"Biomark Insights"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"16122","DOI":"10.18632\/oncotarget.15109","volume":"8","author":"Nagaraj S.","year":"2017","unstructured":"Nagaraj S, Laskowska-Kaszub K, D\u0119bski KJ, Wojsiat J, D\u0105browski M, Gabryelewicz T, Ku\u017anicki J, Wojda U. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer\u2019s disease patients from non-demented subjects.","journal-title":"Oncotarget"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jalz.2015.12.012","volume":"12","author":"Keller A.","year":"2016","unstructured":"Keller A, Backes C, Haas J, Leidinger P, Maetzler W, Deuschle C, Berg D, Ruschil C, Galata V, Ruprecht K, St\u00e4hler C, W\u00fcrstle M, Sickert D, Gogol M, Meder B, Meese E. Validating Alzheimer\u2019s disease micro RNAs using next-generation sequencing.","journal-title":"Alzheimers Dement"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/gb-2013-14-7-r78","volume":"14","author":"Leidinger P.","year":"2013","unstructured":"Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J, Ruprecht K, Paul F, St\u00e4hler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A. A blood based 12-miRNA signature of Alzheimer disease patients.","journal-title":"Genome Biol"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/mp.2014.127","volume":"20","author":"Cheng L.","year":"2015","unstructured":"Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A, Martins RN, Rowe CC, Macaulay SL, Masters CL, Hill AF. Prognostic serum miRNA biomarkers associated with Alzheimer\u2019s disease shows concordance with neuropsychological and neuroimaging assessment.","journal-title":"Mol Psychiatry"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4137\/BMI.S25132","volume":"10","author":"Satoh J.","year":"2015","unstructured":"Satoh J, Kino Y, Niida S. MicroRNA-Seq Data Analysis Pipeline to Identify Blood Biomarkers for Alzheimer\u2019s Disease from Public Data.","journal-title":"Biomark Insights"},{"key":"ref=70","first-page":"87","volume":"31","author":"Yang T.T.","year":"2018","unstructured":"Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC. The Serum Exosome Derived MicroRNA-135a, -193b, and -384 Were Potential Alzheimer\u2019s Disease Biomarkers.","journal-title":"Biomed Environ Sci"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2147\/CIA.S107037","volume":"11","author":"Luo Q.","year":"2016","unstructured":"Luo Q, Chen Y. Long noncoding RNAs and Alzheimer\u2019s disease.","journal-title":"Clin Interv Aging"},{"key":"ref=72","first-page":"4694","volume":"10","author":"Deng Y.","year":"2017","unstructured":"Deng Y, Xiao L, Li W, Tian M, Feng X, Feng H, Hou D. Plasma long noncoding RNA 51A as a stable biomarker of Alzheimer\u2019s disease.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13195-017-0335-x","volume":"10","author":"Duits F.H.","year":"2018","unstructured":"Duits FH, Brinkmalm G, Teunissen CE, Brinkmalm A, Scheltens P, Van der Flier WM, Zetterberg H, Blennow K. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer\u2019s disease.","journal-title":"Alzheimers Res Ther"},{"key":"ref=74","doi-asserted-by":"crossref","unstructured":"Kiddle, S.J.; Steves, C.J.; Mehta, M.; Simmons, A.; Xu, X.; Newhouse, S.; Sattlecker, M.; Ashton, N.J.; Bazenet, C.; Killick, R.; Adnan, J.; Westman, E.; Nelson, S.; Soininen, H.; Kloszewska, I.; Mecocci, P.; Tsolaki, M.; Vellas, B.; Curtis, C.; Breen, G.; Williams, S.C.; Lovestone, S.; Spector, T.D.; Dobson, R.J. Plasma protein biomarkers of Alzheimer\u2019s disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. Transl. Psychiatry, 2015. 5e584 [http:\/\/dx.doi.org\/10.1038\/tp.2015.78] [PMID: 26080319]","DOI":"10.1038\/tp.2015.78"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3233\/JAD-160913","volume":"56","author":"Shen L.","year":"2017","unstructured":"Shen L, Liao L, Chen C, Guo Y, Song D, Wang Y, Chen Y, Zhang K, Ying M, Li S, Liu Q, Ni J. Proteomics Analysis of Blood Serums from Alzheimer\u2019s Disease Patients Using iTRAQ Labeling Technology.","journal-title":"J Alzheimers Dis"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-160622","volume":"57","author":"Cardoso B.R.","year":"2017","unstructured":"Cardoso BR, Hare DJ, Bush AI, Li QX, Fowler CJ, Masters CL, Martins RN, Ganio K, Lothian A, Mukherjee S, Kapp EA, Roberts BR. Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer\u2019s Disease Patients: A Report from the Australian Imaging, Biomarker","journal-title":"J Alzheimers Dis"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/gps.4274","volume":"30","author":"Suzuki I.","year":"2015","unstructured":"Suzuki I, Noguchi M, Arito M, Sato T, Omoteyama K, Maedomari M, Hasegawa H, Suematsu N, Okamoto K, Kato T, Yamaguchi N, Kurokawa MS. Serum peptides as candidate biomarkers for dementia with Lewy bodies.","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3233\/JAD-141266","volume":"43","author":"Muenchhoff J.","year":"2015","unstructured":"Muenchhoff J, Poljak A, Song F, Raftery M, Brodaty H, Duncan M, McEvoy M, Attia J, Schofield PW, Sachdev PS. Plasma protein profiling of mild cognitive impairment and Alzheimer\u2019s disease across two independent cohorts.","journal-title":"J Alzheimers Dis"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/01616412.2017.1281195","volume":"39","author":"Kitamura Y.","year":"2017","unstructured":"Kitamura Y, Usami R, Ichihara S, Kida H, Satoh M, Tomimoto H, Murata M, Oikawa S. Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer\u2019s disease.","journal-title":"Neurol Res"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.exger.2013.12.001","volume":"50","author":"Marksteiner J.","year":"2014","unstructured":"Marksteiner J, Imarhiagbe D, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C. Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer\u2019s disease and mild cognitive impairment: a pilot-study.","journal-title":"Exp Gerontol"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jalz.2013.09.016","volume":"10","author":"Sattlecker M.","year":"2014","unstructured":"Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S, Johnston C, Killick R, Simmons A, Westman E, Hodges A, Soininen H, K\u0142oszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Dobson RJ. Alzheimer\u2019s disease biomarker discovery using SOMAscan multiplexed protein technology.","journal-title":"Alzheimers Dement"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3233\/JAD-131088","volume":"38","author":"Lundstr\u00f6m S.L.","year":"2014","unstructured":"Lundstr\u00f6m SL, Yang H, Lyutvinskiy Y, Rutishauser D, Herukka SK, Soininen H, Zubarev RA. Blood plasma IgG Fc glycans are significantly altered in Alzheimer\u2019s disease and progressive mild cognitive impairment.","journal-title":"J Alzheimers Dis"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3233\/JAD-150553","volume":"49","author":"Edwards M.","year":"2016","unstructured":"Edwards M, Hall J, Williams B, Johnson L, O\u2019Bryant S. Molecular markers of amnestic mild cognitive impairment among Mexican Americans.","journal-title":"J Alzheimers Dis"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/nmt-2015-0009","volume":"6","author":"Villarreal A.E.","year":"2016","unstructured":"Villarreal AE, O\u2019Bryant SE, Edwards M, Grajales S, Britton GB. Serum-based protein profiles of Alzheimer\u2019s disease and mild cognitive impairment in elderly Hispanics.","journal-title":"Neurodegener Dis Manag"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.dadm.2015.12.003","volume":"3","author":"O\u2019Bryant S.E.","year":"2015","unstructured":"O\u2019Bryant SE, Lista S, Rissman RA, Edwards M, Zhang F, Hall J, Zetterberg H, Lovestone S, Gupta V, Graff-Radford N, Martins R, Jeromin A, Waring S, Oh E, Kling M, Baker LD, Hampel H. Comparing biological markers of Alzheimer\u2019s disease across blood fraction and platforms: Comparing apples to oranges.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WAD.0b013e31826d597a","volume":"27","author":"Llano D.A.","year":"2013","unstructured":"Llano DA, Devanarayan V, Simon AJ. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138866","volume":"11","author":"Korolev I.O.","year":"2016","unstructured":"Korolev IO, Symonds LL, Bozoki AC. Predicting Progression from Mild Cognitive Impairment to Alzheimer\u2019s Dementia Using Clinical, MRI, and Plasma Biomarkers via Probabilistic Pattern Classification.","journal-title":"PLoS One"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3233\/JAD-132102","volume":"40","author":"Yang H.","year":"2014","unstructured":"Yang H, Lyutvinskiy Y, Herukka SK, Soininen H, Rutishauser D, Zubarev RA. Prognostic polypeptide blood plasma biomarkers of Alzheimer\u2019s disease progression.","journal-title":"J Alzheimers Dis"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.neuroimage.2014.08.041","volume":"102","author":"Nazeri A.","year":"2014","unstructured":"Nazeri A, Ganjgahi H, Roostaei T, Nichols T, Zarei M. Imaging proteomics for diagnosis, monitoring and prediction of Alzheimer\u2019s disease.","journal-title":"Neuroimage"},{"key":"ref=90","first-page":"2415","volume":"2016","author":"Jammeh E.","year":"2016","unstructured":"Jammeh E, Zhao P, Carroll C, Pearson S, Ifeachor E. Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer\u2019s disease.","journal-title":"Conf Proc IEEE Eng Med Biol Soc"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3233\/JAD-141149","volume":"43","author":"Zhao X.","year":"2015","unstructured":"Zhao X, Lejnine S, Spond J, Zhang C, Ramaraj TC, Holder DJ, Dai H, Weiner R, Laterza OF. A candidate plasma protein classifier to identify Alzheimer\u2019s disease.","journal-title":"J Alzheimers Dis"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.dadm.2016.06.004","volume":"3","author":"O\u2019Bryant S.E.","year":"2016","unstructured":"O\u2019Bryant SE, Edwards M, Johnson L, Hall J, Villarreal AE, Britton GB, Quiceno M, Cullum CM, Graff-Radford NR. A blood screening test for Alzheimer\u2019s disease.","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jprot.2017.12.018","volume":"178","author":"Reumiller C.M.","year":"2018","unstructured":"Reumiller CM, Schmidt GJ, Dhrami I, Umlauf E, Rappold E, Zellner M. Gender-related increase of tropomyosin-1 abundance in platelets of Alzheimer\u2019s disease and mild cognitive impairment patients.","journal-title":"J Proteomics"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13024-016-0095-2","volume":"11","author":"Jaeger P.A.","year":"2016","unstructured":"Jaeger PA, Lucin KM, Britschgi M, Vardarajan B, Huang RP, Kirby ED, Abbey R, Boeve BF, Boxer AL, Farrer LA, Finch N, Graff-Radford NR, Head E, Hofree M, Huang R, Johns H, Karydas A, Knopman DS, Loboda A, Masliah E, Narasimhan R, Petersen RC, Podtelezhnikov A, Pradhan S, Rademakers R, Sun CH, Younkin SG, Miller BL, Ideker T, Wyss-Coray T. Network-driven plasma proteomics expose molecular changes in the Alzheimer\u2019s brain.","journal-title":"Mol Neurodegener"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3233\/JAD-160025","volume":"53","author":"Kang S.","year":"2016","unstructured":"Kang S, Jeong H, Baek JH, Lee SJ, Han SH, Cho HJ, Kim H, Hong HS, Kim YH, Yi EC, Seo SW, Na DL, Hwang D, Mook-Jung I. PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer\u2019s Disease.","journal-title":"J Alzheimers Dis"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.freeradbiomed.2013.08.001","volume":"65","author":"Sultana R.","year":"2013","unstructured":"Sultana R, Baglioni M, Cecchetti R, Cai J, Klein JB, Bastiani P, Ruggiero C, Mecocci P, Butterfield DA. Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease.","journal-title":"Free Radic Biol Med"},{"key":"ref=97","volume":"8","author":"Kim S.","year":"2013","unstructured":"Kim S, Swaminathan S, Inlow M, Risacher SL, Nho K, Shen L, Foroud TM, Petersen RC, Aisen PS, Soares H, Toledo JB, Shaw LM, Trojanowski JQ, Weiner MW, McDonald BC, Farlow MR, Ghetti B, Saykin AJ. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel.","journal-title":"PLoS One"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/165695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T03:23:51Z","timestamp":1605065031000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/165695\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":97,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,6,19]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x16666180926123722","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,19]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}